24 Feb. 2021
BioVersys, TASK and GSK receive 2.7 million Euro from EDCTP for Phase 2a Clinical Trial
BioVersys and consortium partners TASK Foundation and GSK have been awarded 2.7 million Euro from European and Developing Countries Trial Partnership...
12 Jan. 2021
BioVersys reports first dosing of BVL-GSK098 in clinical Phase I
BioVersys is proud to announce together with its partner GSK the first dosing of our Tuberculosis asset BVL-GSK098 in clinical Phase I. This is a grea...
18 Nov. 2020
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100
Today marks the start of the World Antimicrobial Awareness Week 2020 by the WHO, underlining once more the incredibly important health emergency that...
01 Sep. 2020
BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development
BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candid...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
